Mouse model of hematogenous implant-related *Staphylococcus aureus* biofilm infection reveals therapeutic targets

Yu Wang\(^a\), Lily I. Cheng\(^b\), David R. Helfer\(^c\), Alyssa G. Ashbaugh\(^d\), Robert J. Miller\(^e\), Alexander J. Tzomides\(^f\), John M. Thompson\(^g\), Roger V. Ortines\(^h\), Andrew S. Tsai\(^i\), Haiyun Liu\(^j\), Carly A. Dillen\(^n\), Nathan K. Archer\(^a\), Taylor S. Cohen\(^d\), Christine Tkaczyk\(^d\), C. Kendall Stover\(^d\), Bret R. Sellman\(^d\), and Lloyd S. Miller\(^a,c,e,f,1\)

\(^a\)Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231; \(^b\)Department of Translational Science, MedImmune, LLC, Gaithersburg, MD 20878; \(^c\)Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287; \(^d\)Department of Infectious Diseases, MedImmune, Gaithersburg, MD 20878; \(^e\)Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287; and \(^f\)Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD 21218

Edited by Jeff F. Miller, University of California, Los Angeles, CA, and approved May 24, 2017 (received for review February 28, 2017)

Infections of implantable medical devices are associated with bacterial biofilms that form on the implanted foreign materials and are impervious to antibiotic and immune cell penetration (1, 2), leading to chronic and difficult-to-treat infections (3, 4). In particular, the treatment of prosthetic joint infections (PJI) (i.e., infection of knee and hip joint prostheses) is exceedingly difficult because it typically involves reoperations to remove the infected prosthesis, prolonged courses of systemic antibiotics, and delayed reimplantation of a new prosthesis, all of which contribute to extended disability and rehabilitation and increased morbidity, mortality, and healthcare costs (5, 6). Most PJI and other implant-related infections are thought to occur by invading bacteria during surgery or in the immediate postoperative period (7, 8). However, hematogenous infections, which represent up to 20% of PJI, are especially problematic because they can occur at any time after implantation by bacteria from a remote source of infection or exposure seeding a previously well-functioning prosthesis through the bloodstream (9–11). *Staphylococcus aureus* is a particularly clinically relevant pathogen because it is the most common cause of PJI in humans (12, 13), and *S. aureus* bacteremia results in a hematogenous PJI in 30–40% of patients with joint prostheses in place at the time of *S. aureus* bacteremia (9, 11, 14). Furthermore, community-associated methicillin-resistant *S. aureus* (CA-MRSA) clinical isolates are increasingly becoming resistant to antibiotics (15, 16), underscoreing the unmet clinical need for therapeutic alternatives to conventional antibiotics.

In individuals with implantable medical devices, systemic antibiotics are currently used as prophylactic therapy against hematogenous implant infections before medical and surgical procedures associated with a transient bacteremia (e.g., colonoscopies and urologic and dental procedures) (17–19). A major concern is that the efficacy of antibiotic prophylaxis has been declining because of the increasing emergence of multidrug resistant bacteria (20). Furthermore, the impact of broad-spectrum antibiotics on the beneficial microbiota can also be a risk factor for other infections and inflammatory diseases, and antibiotic stewardship programs are aiming to reduce overall antibiotic use (21). Thus, a greater understanding of the bacterial pathologic mechanisms of hematogenous implant infections is essential to develop new, alternative therapies for prevention or treatment.

Prior preclinical models of PJI or orthopedic implant infections have involved direct insertion of an implant with bacteria already adherent to its surface (22, 23), direct inoculation of bacteria at the surgical site of an implant (24–26), or bacteremia resulting in septic arthritis in the absence of an implant (27, 28). Although each of these models has features of a hematogenous implant infection, they do not fully recapitulate the spread of the bacteria at the surgical site of an implant (24–26), or bacteremia resulting in septic arthritis in the absence of an implant (27, 28). Although each of these models has features of a hematogenous implant infection, they do not fully recapitulate the spread of the }

**Hematogenous implant-related infections** are an important clinical problem because bacteria spread from the bloodstream to a previously well-functioning implant and result in infectious complications and failure of a medical device or prosthesis. To study these infections, we developed a preclinical animal model of a *Staphylococcus aureus* hematogenous implant infection with the capability to monitor noninvasively and longitudinally the dissemination of the bacteria from the bloodstream to a surgically placed orthopedic implant. Using this model, α-toxin and clumping factor A were identified as key factors that contributed to the pathogenesis of these infections by promoting biofilm formation. Finally, neutralizing antibodies against these factors provided a targeted, nonantibiotic alternative approach to help prevent these difficult-to-treat and costly infections.

**Significance**

Hematogenous implant-related infections are an important clinical problem because bacteria spread from the bloodstream to a previously well-functioning implant and result in infectious complications and failure of a medical device or prosthesis. To study these infections, we developed a preclinical animal model of a *Staphylococcus aureus* hematogenous implant infection with the capability to monitor noninvasively and longitudinally the dissemination of the bacteria from the bloodstream to a surgically placed orthopedic implant. Using this model, α-toxin and clumping factor A were identified as key factors that contributed to the pathogenesis of these infections by promoting biofilm formation. Finally, neutralizing antibodies against these factors provided a targeted, nonantibiotic alternative approach to help prevent these difficult-to-treat and costly infections.


Conflict of interest statement: L.S.M. has received grant support from MedImmune, LLC for the work reported in this paper; grant support from Pfizer, Regeneron, and the Chan Soon-Shiong Nanthealth Foundation; and consulting fees from Noveome Biotherapeutics and the Chan Soon-Shiong Nanthealth Foundation that are unrelated to the work reported in this paper. L.I.C., T.S.C., C.T., C.K.S., and B.R.S. are associated with MedImmune, LLC, a subsidiary of AstraZeneca, and may hold AstraZeneca stock.

This article is a *PNAS* Direct Submission.

\(^1\)To whom correspondence should be addressed. Email: lloydmiller@jhmi.edu.
bacteria from the bloodstream to the site of an implant. To the best of our knowledge, two prior preclinical models of hematogenous orthopedic implant infections in rabbits (29) and rats (30) have described the hematogenous spread of infection to the implant and surrounding bone and joint tissue at static time points but have not investigated the temporal and spatial dynamics of the infection over time or determined relevant pathogenic factors.

Therefore, we chose to develop a mouse model of a hematogenous orthopedic implant infection using a bioluminescent CA-MRSA strain in conjunction with in vivo whole-animal optical imaging to monitor the hematogenous infection noninvasively and longitudinally and to identify specific virulence factors for potential therapeutic targets.

Results

Development of a Model of Hematogenous Implant Infection. To study a hematogenous implant infection beginning with bacteremia and resulting in an implant infection, we combined surgical placement of an orthopedic implant, bioluminescent bacteria, and in vivo whole-animal bioluminescence imaging (BLI) techniques. We did so by first placing an orthopedic-grade titanium Kirschner wire (K-wire) into the right femurs of C57BL/6 mice with the end protruding into the knee joint using aseptic surgical technique (Fig. 1A). The groups of mice were infected i.v. 21 d post surgery, after the sterile inflammation caused by the surgical procedure had resolved, with one of three different inocula (\(1 \times 10^5, 5 \times 10^5, \) and \(1 \times 10^7\) cfu) of a stably bioluminescent CA-MRSA strain, SAP231, and the infection was monitored with in vivo BLI on days 0, 3, 7, 14, 21, and 28 post inoculation. SAP231 has virulence similar to its parent NRS384 strain, which is a CA-MRSA USA300 strain previously isolated from a major skin and soft tissue infection outbreak (31). At early time points (3–14 d post inoculation), the BLI signals could be visualized in internal organs, especially in the kidneys and bladder, of mice that had received the \(5 \times 10^6\) and \(1 \times 10^7\) cfu inocula (Fig. 1B). By day 28 post inoculation, all three inocula resulted in the accumulation of BLI signals in the leg with the surgical implant [hereafter, the “(+1) implant surgical leg”] with residual in vivo BLI signals in the bladder. In addition, the percentage of mice with BLI signal in the (+1) implant surgical leg correlated with the amount of bacteria inoculated, because the percentage was significantly higher with the \(1 \times 10^7\) cfu inoculum than with the \(1 \times 10^6\) or \(5 \times 10^6\) cfu inocula on days 14–28 (\(P < 0.05\)) (Fig. 1C). At day 28, mice were killed, and in vivo BLI was performed on internal organs as well as the (+1) implant surgical legs and the contralateral nonsurgical legs (Fig. 1D). With all inocula, and particularly with the \(1 \times 10^7\) cfu inoculum, BLI signals were seen in one (or both) kidneys and in most of the (+1) implant surgical legs. Variable BLI signals were also seen in the liver and contralateral surgical legs, but no BLI signals were seen in the heart or spleen. The \(1 \times 10^7\) cfu inoculum was selected for use in all subsequent experiments because it resulted in a higher percentage of BLI signals in the (+1) implant surgical leg than the other inocula.

![Fig. 1. Model of hematogenous implant infection. (A) Timeline of hematogenous infection of an orthopedic implant. (B) Representative images of in vivo BLI signals on a color scale overlaid on a grayscale photograph of mice with different S. aureus inocula. (C) Percentage of mice with detectable BLI signal from the (+1) implant surgical leg with three different S. aureus inocula. (D) Representative images of ex vivo BLI signal from the organs and legs harvested on day 28 from mice inoculated with \(1 \times 10^7\) cfu. Results are representative (B and D) or a compilation (C) of two independent experiments (\(n = 8–9\) mice per group). *\(P < 0.05\), \(1 \times 10^5\) cfu vs. \(1 \times 10^6\) or \(5 \times 10^6\) cfu groups, as measured by a two-way ANOVA (performed on days 14–28).](image-url)
In prior models of septic arthritis (in the absence of surgery or an implant), an i.v. *S. aureus* challenge had an increased propensity to spread to the knee joints of mice (27, 28). To evaluate the propensity for the hematogenous infection to spread to the knee joints of mice in the presence and absence of an implant, we used our model of hematogenous orthopedic implant infection and evaluated BLI signals from (i) the (+) implant surgical leg, (ii) the (−) implant surgical leg that had the identical surgical procedure performed but without the placement of an implant, and (iii) the respective nonsurgical contralateral leg (Fig. 2).

The percentage of mice with BLI signals on days 3–28 (P < 0.05) and the quantified in vivo BLI signals from the (+) implant surgical legs on days 7–28 (P < 0.05) were significantly higher than in the (−) implant surgical legs or nonsurgical legs (Fig. 2 A and B). To confirm these results obtained with in vivo BLI, ex vivo cfu were obtained from homogenized bone and joint tissue specimens on day 28 (Fig. 2 C). The (+) implant surgical legs had significantly greater ex vivo cfu than the (−) implant surgical legs or nonsurgical legs, whereas there was no significant difference in ex vivo cfu between the (−) implant surgical legs and nonsurgical legs. Therefore, the presence of the implant resulted in a marked propensity for a hematogenous infection compared with the (−) implant surgical legs or the nonsurgical legs. To evaluate the propensity of infection further, we determined the numbers of mice with (+) and without (−) implant placement in which ex vivo cfu present were in the surgical and nonsurgical legs; these data are presented in a Euler Diagram (Fig. 2 D). The number of mice with an infection in the surgical leg in the (+) implant group was nearly double the number of mice with an infection in the surgical leg in the (−) implant group (21 vs. 12, P < 0.05). Taken together, these results show that the presence of the implant was a major determinant of the propensity for hematogenous infection.

**Histopathology of the Hematogenous Implant Infection.** To evaluate the location of the biofilm formation on the implant and the infection in the surrounding tissue and bone, the implants and bone/joint specimens were harvested on day 28, and the implants were stained with a live/dead bacterial stain. The green (live and dead bacteria) and red (dead bacteria) fluorescent signals of the bacteria adherent to the implant were localized mostly at the distal end of the implant that was in contact with the distal physis of the femur (Fig. 3 A). Histology showed marked reactive bony changes in the cortical, trabecular bone, and the physis, an abundance of mature neutrophils in the joint tissue (arthritis) and bone marrow cavity (osteomyelitis), and abscess formation within the marrow cavity of the cortex and distal end of the femur, all indicative of infection (Fig. 3 B). These data suggest that the bacteria preferentially formed a biofilm on the implant at a site adjacent to the physis, and the abundance of neutrophils
in bone and joint tissue is consistent with the presence of both osteomyelitis and septic arthritis.

**α-Toxin and Clumping Factor A Promote in Vitro Biofilm Formation.** Next, we hypothesized that virulence factors involved in biofilm formation in vitro would contribute to the pathogenesis of the hematogenous orthopedic implant infection in vivo. Therefore, we first evaluated the effect of anti-α-toxin (AT) (MEDI4893*) and anti-clumping factor A (CfA) (11H10) mAbs on in vitro biofilm formation. These mAbs are high-affinity, functional mAbs reported to reduce disease severity in various *S. aureus* disease models (32, 33). AT is a secreted pore-forming toxin (34) found to promote biofilm formation in vitro (35, 36), and to contribute to immune evasion in a murine model of orthopedic implant infection (37). CfA is a surface-expressed fibrinogen-binding adhesin that has been shown to promote biofilm-like aggregations in synovial fluid (38) [providing a role for CfA in septic arthritis (39, 40)] and is highly expressed in human orthopedic implant infections (41).

The anti-AT and anti-CfA mAbs (0.5 μg/mL each) were first determined to have no effect, either alone or in combination, on the planktonic growth of NRS384 in broth culture (Fig. 4A). Using an established microtiter biofilm assay (42), the anti-AT and anti-CfA mAbs (0.5 μg/mL each) were included alone and in combination at the beginning of the assay, and biofilm formation of NRS384 was assessed after 12 or 24 h. The anti-CfA mAb and the anti-AT/CfA mAb combination, but not the anti-AT mAb alone, inhibited biofilm formation after 12 and 24 h compared with the isotype control mAb (Fig. 4B and C). In light of prior reports demonstrating that AT expression was associated with biofilm formation in vitro (35, 36), we evaluated the twofold mAb concentration (1 μg/mL). Again, neither mAb alone nor the mAb combination had any effect on the planktonic growth of NRS384 in broth culture (Fig. 4D). After 24 h, the anti-AT and anti-AT/CfA mAb combination reduced biofilm formation significantly (*P* < 0.05), and there was a trend for the anti-AT mAb in inhibiting biofilm formation that approached statistical significance (*P* = 0.058) (Fig. 4E). After 24 h, anti-AT, anti-CfA, and the anti-AT/anti-CfA mAb combination all inhibited biofilm formation significantly (*P* < 0.05) (Fig. 4F). Thus, although the anti-AT mAb had a modest dose-dependent effect on in vitro biofilm formation, the anti-CfA mAb had the greater effect and was responsible for a majority of the inhibition seen with the anti-AT/anti-CfA combination.

**mAbs Against AT and CfA Reduce a Hematogenous Implant Infection in Vivo.** To determine if the anti-AT and anti-CfA mAbs would
provide protection against an in vivo hematogenous implant infection, the mAbs were administered i.v. as single agents 1 d before i.v. S. aureus inoculation in the model of hematogenous orthopedic implant infection. Both the anti-AT mAb and the anti-ClfA mAb resulted in a significant decrease in the percentage of mice with in vivo BLI signal from the (+) implant surgical legs on days 3–28 (P < 0.001) (Fig. 5A). However, neither the anti-AT mAb nor the anti-ClfA mAb resulted in significant differences in the quantified in vivo BLI signals from the (+) implant surgical legs or ex vivo cfu from the surgical and nonsurgical legs on day 28 (Fig. 5B and C). Thus, the individual mAbs reduced the propensity for the (+) implant surgical legs to become infected but did not alter the actual bacterial burden in the surgical or nonsurgical legs.

Given that the anti-AT and anti-ClfA mAbs exhibit distinct mechanisms of action and that each mAb decreased the percentage of mice with infection in the (+) implant surgical leg, and because we previously had seen improved activity of the mAb combination over monotherapy in a murine model of bacteremia (32), we evaluated the effect of targeting both AT and ClfA by administering the mAbs in combination. Prophylaxis with the anti-AT/anti-ClfA mAb combination significantly decreased the percentage of mice with in vivo BLI signals and reduced in vivo BLI signals in the (+) implant surgical leg compared with the control mAb on days 3–28 (P < 0.05) (Fig. 6A and B). In addition, the anti-AT/anti-ClfA mAb combination significantly reduced ex vivo cfu from bone/joint tissue from the (+) implant surgical legs on day 28 as compared with the control mAb (Fig. 6C). To determine whether the anti-AT/anti-ClfA combination also impacted the propensity for the hematogenous implant infection, we evaluated the ex vivo cfu present in the surgical and nonsurgical legs of mice with (+) implant placement (Fig. 6D). The anti-AT/anti-ClfA mAb combination resulted in nearly a 50% reduction in the numbers of mice with infection in the (+) implant surgical legs compared with...
vested at day 28. The implants from mice treated with the control microsopy to evaluate biofilm formation on the implants har-

Wang et al. PNAS

the control mAb (11 vs. 20, respectively, \( P < 0.05 \)). Moreover, the anti-AT/anti-ClfA mAb combination reduced the overall propensity of infection, because the numbers of mice with no detectable cfu in both the surgical and nonsurgical legs was increased twofold compared with the control mAb (15 vs. 7, re- spectively) \( (P < 0.05) \). Finally, we performed scanning electron microscopy to evaluate biofilm formation on the implants har-

the control (ctrl) mAb, anti-AT mAb, or anti-ClfA mAb (22.5 mg/kg, i.v.). (A) The percentage of mice with detectable in vivo BLI signals from the (+) implant surgical leg. (B) Mean in vivo BLI from the (+) implant surgical leg (mean maximum flux expressed as photons s\(^{-1}\) cm\(^{-2}\) steradian \( \pm \) SEM). (C) Ex vivo cfu (solid horizontal lines indicate geometric mean) from the (+) implant surgical leg and the nonsurgical leg; dotted horizontal dotted lines indicate the limit of detection (100 cfu). \( ^{1}P < 0.01 \), \( ^{2}P < 0.001 \), vs. control mAb, as measured by a two-way ANOVA (performed on days 3–28) (A and B) or a two-tailed Mann–Whitney \( U \) test (C). Results are a compilation of five in- dependent experiments (\( n = 28 \) mice per group). n.s., not significant.

mice treated with anti-AT/anti-ClfA combination therapy had only occasional coccoid bacteria (blue arrowheads in Fig. 6E) but lacked appreciable biofilm formation (white arrows in Fig. 6E). Taken together, a mAb combination targeting both AT and ClfA markedly reduced the hematogenous implant infec-

Discussion

S. aureus hematogenous implant infection is a major complica-

tion that impedes the long-term success of implantable medical devices and prostheses (9–11). Here we report the development of a mouse model of a hematogenous orthopedic implant in-

fection using a virulent bioluminescent CA-MRSA strain (43) and in vivo whole-animal imaging to monitor the dy-

namics of the infection beginning with bacteremia and resulting in seeding and infection of the surgically placed implant and surrounding bone and joint tissue. This model provided several insights into factors that contribute to the pathogenesis of he-

matogenous orthopedic infections.

First, the BLI signals at early time points after i.v. challenge were disseminated throughout the internal organs of the mice, especially in the kidneys and bladder. However, as the infection progressed over the course of 28 d, the bacterial signals accumu-

lated preferentially at the site of surgically implanted legs in most of the mice. In general, after a S. aureus i.v. challenge in mice, there is a predilection for the bacteria to cause a septic arthritis in the knee joints (27, 28). However, the presence of the orthopedic implant was a major determinant for the hematoge-

nous implant infection, which occurred 70% of the time. Indeed, the number of mice with an infection in the (+) implant surgical leg was almost double the number of mice with an infection in the (−) implant surgical leg and almost three times the number with an infection in nonsurgical legs (Fig. 2D).

Second, the anatomical location where the bacteria seeded the implant, formed a biofilm, and caused an infection in the sur-

rounding bone and joint tissue preferentially involved the area adjacent to the distal femoral physis. Although the precise rea-

son for this anatomic location is unclear, the physis has an ex-

cellent blood supply from the metaphyseal vascular plexus fed by the metaphyseal arteries and adjacent vascularity consisting of the diaphyseal nutrient artery proximally, epiphyseal arteries distally, and capillary network from the perichondral arteries circumferentially. Therefore, it is likely that the bacteria in the blood hematogenously seeded the implant through this well-

vascularized area. Alternatively (or in addition), the bacteria might have had a propensity to adhere to the implant and pro-

duce a biofilm at this location because of the continuous source of nutrients supplied by the direct and abundant blood flow to the physis. It should be noted that some of the mice did not de-

velop a hematogenous implant infection, because on day 28 there were no detectable cfu from the implants or surrounding joint tissue of these mice. These mice also had reduced and eventually absent BLI signals at the surgical site at earlier time points. The reason for the lack of implant infection in some mice is unclear, but bacterial dissemination, biofilm formation, and proliferation at the surgical site are likely important determinants for the develop-

ment of a persistent implant-related infection.

Third, fibronectin binding (in particular binding-enhancing polymorphisms in fibronectin-binding proteins A and B) was previously identified as an important pathogenic determinant for hematogenous implant infections involving cardiac devices in humans (44). However, a similar role for fibronectin binding was not found for hematogenous PJIs in humans (45). To identify potential pathogenic factors that contributed to the hematogenous orthopedic implant infection in our mouse model, we investigated S. aureus AT and ClfA because they are involved in biofilm for-

mation in vitro (35, 36) and in human synovial fluid specimens ex vivo (38) and have been implicated in septic arthritis (39, 40) and
primary orthopedic implant infections in mice and humans (37, 41). Neutralizing the activity of AT and ClfA with human anti-AT and anti-ClfA mAbs (32, 46) inhibited biofilm formation in vitro. The anti-ClfA mAb alone was a potent inhibitor of biofilm formation at the high concentration and at 24 h of the assay, whereas the anti-AT mAb significantly inhibited biofilm formation only at static time points after infection (24, 47), and the inhibition of AT might have had a similar effect in our hematogenous implant-related biofilm infection.

Finally, the anti-AT and anti-ClfA mAbs were evaluated alone and in combination in our model of hematogenous orthopedic implant infection. Prophylaxis with the anti-ClfA or anti-AT mAb alone modestly reduced the propensity of the infection but did not reduce the bacterial burden in the surgical or nonsurgical legs. In contrast, targeting both AT and ClfA with the anti-AT/anti-ClfA mAb combination resulted in more than a 50% reduction in the propensity for the hematogenous implant infection, decreased bacterial burden in the (+) implant surgical legs, and reduced biofilm formation on the implants. Similar to the improved activity of the mAb combination reported in a murine model of bacteremia (32), the improved efficacy of the mAb combination in this model likely resulted from targeting complementary virulence mechanisms, including neutralization of AT-mediated tissue damage, inflammation and immune evasion, inhibition of ClfA-mediated fibrinogen binding and bacterial agglutination in the synovium (38), and anti-ClfA–mediated opsonophagocytic killing of S. aureus (32). In addition, AT has been shown to promote host cell lysis to provide a nutrient source for the bacteria in a model of S. aureus vaginal mucosal biofilm infection (47), and the inhibition of AT might have had a similar effect in our hematogenous implant-related biofilm infection.

Previous models of hematogenous orthopedic implant infections in rabbits and rats described the spread of the bacteremia infection to a surgically placed implant and surrounding bone and joint tissue but only at static time points after infection (29, 30). Other models studied bacteremia that resulted in septic arthritis in mice but in the absence of a surgically placed implant (27, 28). The present model of S. aureus hematogenous orthopedic infection represents an advance over these prior models because the recently developed bright bioluminescent S. aureus strain in combination with in vivo BLI provided an opportunity
to monitor the anatomic dissemination of the infection in the same animals noninvasively and longitudinally over time. Therefore, data regarding both the spatial and temporal spread of the hematogenous infection and the effect of anti-AT and anti-CIFA mAb therapy could be obtained.

This study has several limitations. First, the study was performed using a USA300 strain, which is the predominant S. aureus isolate that causes CA-MRSA infections in the United States. However, prior work found that USA200 S. aureus strains producing toxic shock syndrome toxin-1 (TSST-1) can cause hematogenous and osteomyelitis infections (48, 49). Because USA200 strains produce little or no AT because of a stop codon in the AT gene (50), the anti-AT mAb will likely not have an effect in USA200 or in other strains that do not produce AT. Future work will evaluate anti-CIFA mAb therapy in combination with mAbs against additional targets for broader coverage against USA200 and other S. aureus isolates. In addition, S. aureus superantigens, such as TSST-1, and certain cytolytic toxins, such as Panton–Valentine leukocidin, are important virulence factors in humans but have less involvement in mouse models (51). These and other differences between the species should be taken into account when translating our findings to humans.

Taken together, our results using a model of S. aureus hematogenous orthopedic infection that provided the opportunity for noninvasive and longitudinal monitoring of the dissemination of the bacteria and the implant of bone and joint tissue as previously described in the Guide for the Care and Use of Laboratory Animals (52).

**Methods**

**S. aureus Strain.** The bioluminescent SAP231 strain was used in all in vivo experiments and was generated as previously described from NRS384, a well-described USA300 CA-MRSA isolate obtained from a skin infection outbreak in the Mississippi prison system (43). SAP231 possesses a stably integrated modified luxABCDE operon from the bacterial insect pathogen *Photobacterium luminescens*. Live and metabolically active SAP231 bacteria constitutively emit a blue-green light, which is maintained in all progeny without selection.

**Bacterial Preparation.** S. aureus bacteria were streaked onto tryptic soy agar (TSA) plates [tryptic soy broth (TSB, TSA plus 1.5% Bacto agar)] (BD Biosciences) and grown overnight at 37 °C in a bacterial incubator. Single colonies were picked and cultured in TSB at 37 °C in a shaking incubator (MaxQ HP 420, ThermoFisher) (240 rpm) overnight (16 h), followed by a 1:50 subculture at 37 °C for 2 h to obtain midlogarithmic phase bacteria. The bacteria were pelleted, resuspended in sterile PBS, and washed two times. OD600 was measured to estimate the number of cfu, which was verified after overnight culture on TSA plates.

**Mice.** Ten- to twelve-week-old male C57BL/6 mice were used in all experiments. The mice were originally obtained from Jackson Laboratories and were bred and maintained under specific pathogen-free conditions at an animal facility accredited by the Association for the Accreditation of Laboratory Animal Care (AAALAC)-accredited animal facility at Johns Hopkins University and were housed according to procedures described in the Guide for the Care and Use of Laboratory Animals (52).

**Mouse Model of a Hematogenous Orthopedic Infection.** All procedures were approved by the Johns Hopkins University Animal Use and Care Committee. The surgical procedure was modified from previous work (26). Briefly, mice were anesthetized via inhalation isoflurane (2%), a skin incision was made over the right knee, and the distal right femur was accessed via a medial parapatellar arthrotomy with lateral displacement of the quadriceps-patellar complex. An intramedullary femoral canal was manually reamed with a 25-gauge needle, and an orthopedic-grade titanium K-wire (length 9 mm, diameter 0.6 mm) (Modern Grinding) was surgically placed in a retrograde fashion with 1 mm protruding into the knee joint space. The quadriceps-patellar complex was reduced to midline, and the surgical site was closed with absorbable Vicryl 5–0 sutures. For analgesia, sustained-release buprenorphine (2.5 mg/kg) was administered s.c. at the time of surgery. At 21 d postsurgery, SAP231 at three different inocula (1 × 106, 5 × 106, and 1.0 × 107 cfu) was inoculated i.v. via the retro-orbital vein. All mice with the 1 × 106 cfu and 5 × 106 cfu inoculum survived the bacterial challenge; the 1.0 × 107 cfu inoculum was the 10% lethal dose (LD10), which resulted in slight differences in sample sizes between experiments.

**In Vivo BLI.** In vivo BLI was performed on anesthetized mice (2% isoflurane) using a Lumina III IVIS in vivo imaging system (PerkinElmer) and maximum flux (measured as photons s−1 cm−2 steradian) was measured within a 1 × 10−3-pixel circular region of interest using Living Image software (PerkinElmer) (limit of detection: 3.0 × 103 photons s−1 cm−2 steradian). The bioluminescent signals detected from the infected postsurgical site closely approximate the actual bacterial burden measured by the ex vivo cfu of homogenized bone/joint tissue as previously described (53, 54).

**Ex Vivo cfu Counting.** Mice were killed on day 28 post infection, and the periimplant joint/bone tissue and implants from the surgical and nonsurgical legs were harvested as previously described (53, 54). Bacterial cfu were isolated by homogenizing the tissue (Pro200 Series homogenizer; Pro Scientific) in PBS on ice. Ex vivo cfu were counted after serially diluted joint/bone tissue homogenates were plated overnight on TSA plates.

**Live/Dead Bacterial Staining and Histological Analysis.** Mice were killed on day 28 post infection, and bone/joint specimens were obtained. The K-wire implants were removed by gently pulling the implant proximally so not to disturb the knee joint. Implants were stained using the LIVE/DEAD BacLight Bacterial Viability Kit (Thermo Fisher) according to the manufacturer’s recommendations, and green fluorescent signals (live and dead bacteria) and red fluorescent signals (dead bacteria) were visualized on a fluorescent microscope. All joint/bone tissue specimens were fixed in 10% formalin overnight, decalcified, and embedded in paraffin. Sagittal sections were cut at 4-μm thickness and then were stained with H&E for evaluation under light microscopy by a pathologist.

**Anti-AT and Anti-CIFA mAbs.** Anti-AT mAb (MED48993*), anti-CIFA (11H110), and control human IgG1 type antibody (anti-HIV gp120 R3471) mAbs are fully human antibodies that were generated as previously described (32, 46).

**Planktonic Growth Assay.** NRS384 bacteria were streaked onto TSA plates and grown overnight at 37 °C in a bacterial incubator. Single colonies were picked and cultured in TSB overnight (16 h) at 37 °C in a shaking incubator (240 rpm). The overnight culture then was diluted to an OD600 of 0.1 in fresh TSB containing anti-AT mAb, anti-CIFA mAb, the anti-AT/CIFA mAb combination at low (0.5 μg/mL) and high (1.0 μg/mL) concentrations, or an isotype control mAb (1 or 2 μg/mL, respectively). The OD600 was measured every 30 min for 5 h.

**Microtitre Biofilm Assay.** The in vitro microtitre biofilm assay was performed according to previously described methods (42). Briefly, the NRS384 strain was grown in TSB for 16 h at 240 rpm. The overnight culture then was diluted with fresh TSB supplemented with 3% NaCl and 0.5% glucose, and the bacterial concentration was adjusted to an OD600 of 0.1. The bacteria were grown in TSB supplemented with 3% NaCl and 0.5% glucose in plasma-coated 96-well microtitre plates (Corning) with the addition of anti-AT mAb, anti-CIFA mAb, the anti-AT/anti-CIFA mAb combination at low (0.5 μg/mL) and high (1.0 μg/mL) concentrations, or an isotype control mAb (1 or 2 μg/mL, respectively). The OD600 was measured every 30 min for 5 h.

**Scanning Electron Microscopy.** K-wire implants were removed from the femurs at 28 d after bacterial inoculation and were fixed in buffered 4% formaldehyde/2.5% glutaraldehyde solution overnight (16 h). All K-wire specimens were postfixed in 1% osmium tetroxide in PBS for 2 h followed by subsequent dehydration in a graded ethanol series. Samples then were placed into transitional series of graded ethanol/hexamethyldisilazane (HMDS) mixtures (2:1, 1:1, and 1:2) each for 30 min, and finally into pure HMDS (twice, 30 min each). Specimens were air-dried in a chemical hood before
sputter-coating with a gold-palladium alloy and were imaged using a field-emission scanning electron microscope (JSM-6700 FE-SEM; JEOL).

Statistics. Data were compared using a two-way ANOVA, or two-tailed Fischer exact test, as indicated in the figure legends. All statistical analyses were calculated using Prism software (GraphPad). Data are presented as mean ± SEM, and values of $P < 0.05$ were considered statistically significant.

ACKNOWLEDGMENTS. This work was supported by a sponsored research agreement from MedImmune, LLC through a Johns Hopkins-MedImmune Academic Industry Partnership.